Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple Myeloma

Video

Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.

This content originally appeared on our sister site, OncLive.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
Intellia’s CRISPR Gene Editing Therapy NTLA-2002 Appears to Eliminate Hereditary Angioedema Attacks in Some Patients Following One-Time Treatment

Intellia’s CRISPR Gene Editing Therapy NTLA-2002 Appears to Eliminate Hereditary Angioedema Attacks in Some Patients Following One-Time Treatment

Noah Stansfield
October 27th 2024
Article

Participants in the trial received either a single dose of 25 mg of NTLA-2002, a single dose of 50 mg of NTLA-2002, or a placebo.

William Chou, MD, president and chief executive officer of Passage Bio

Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations

William Chou, MD;Noah Stansfield
October 27th 2024
Article

William Chou, MD, president and chief executive officer of Passage Bio, discussed feedback from a recent Type C meeting with the FDA.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – October 25, 2024

CGTLive Staff
October 25th 2024
Article

Review top news and interview highlights from the week ending October 25, 2024.

Around the Helix: Cell and Gene Therapy Company Updates – October 23, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 23, 2024

Noah Stansfield
October 23rd 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Molly Borchardt, PharmD

Payer Challenges for Patient Access to Autologous Cell and Gene Therapies

Molly Borchardt, PharmD;Phil Cyr, MPH;Erin Lopata, PharmD, MPH;Jason Foster, MBA
October 23rd 2024
Article

Autologous cell and gene therapies show promise but face barriers such as high costs, limited access, and payer concerns over long-term effectiveness.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – October 18, 2024

CGTLive Staff
October 18th 2024
Article

Review top news and interview highlights from the week ending October 18, 2024.

© 2024 MJH Life Sciences

All rights reserved.